Navigation Links
Transgenomic Reports Second Quarter Financial Results
Date:8/11/2011

)756(50)765(50)MODIFIED EBITDA(369)(939)(385)(1,104)TRANSGENOMIC, INC. AND SUBSIDIARYCONDENSED CONSOLIDATED BALANCE SHEETS(Dollars in thousands except per share data)June 30,2011December 31,(unaudited)2010ASSETSCURRENT ASSETS:Cash and cash equivalents

$

2,639$

3,454Accounts receivable

7,1947,601Inventories

3,3093,344Other current assets

860635Total current assets

14,00215,034PROPERTY AND EQUIPMENT, NET1,7711,602OTHER ASSETS:Goodwill

6,2756,275Intangibles

8,5228,962Other assets

130154$

30,700$

32,027LIABILITIES AND STOCKHOLDERS' EQUITYCURRENT LIABILITIES$9,905$8,253OTHER LIABILITIES:Long term debt less current maturities

7,4068,640Preferred stock conversion feature

7,6001,983Preferred Stock Warrant liability

3,0002,351Other long-term liabilities

1,008843Total liabilities

28,91922,070Redeemable Series A convertible preferred stock, $0.1 par value, 3,879,307 shares authorized, 2,586,205 shares issued and outstanding1,6701,457STOCKHOLDERS' EQUITY1118,500$

30,700$

32,027See notes to unaudited condensed consolidated financial statements.
'/>"/>

SOURCE Transgenomic, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Transgenomic to Hold First Quarter Financial Results Conference Call on May 12, 2011
2. Transgenomic, Inc. Enhances FAMILION® Genetic Test Offerings
3. Transgenomic, Inc. Presentations to Describe High-Sensitivity Detection of Cancer Biomarkers at the 2011 American Association for Cancer Research Meeting
4. Transgenomic Announces Discovery of a Novel Technique Which Enhances Analytic Sensitivity of Standard Sanger Sequencing to 1%
5. Reminder Webcast Alert: Transgenomic to Hold Fourth Quarter Financial Results Conference Call on March 11, 2011
6. Transgenomic to Hold Fourth Quarter Financial Results Conference Call on March 11, 2011
7. Transgenomic to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on February 17
8. Transgenomic Reports Third Quarter Financial Results
9. Transgenomic Awarded $1,070,453 From U.S. Government Under the Patient Protection and Affordable Care Act
10. Transgenomic to Hold Third Quarter Financial Results Conference Call on November 15, 2010
11. Transgenomic Develops New Assays to Detect EGFR Mutations Using COLD-PCR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ... July 02, 2015 , ... In’Tech ... surgical instruments in Orthopedics, announced today the acquisition of Turner Medical, Inc ... provider of surgical instruments to the Spine Industry. The acquisition of Turner Medical ...
(Date:7/1/2015)... PARIS , July 1, 2015 ... key developer of biotech crops, today announce a ... generations of insect control traits. "Growers ... the realities of advancing insect resistance. We are ... insect control technology with Genective,s capability in developing ...
(Date:7/1/2015)... ... 2015 , ... The next-generation sequencing (NGS) clinical market is poised for huge ... industry. BCC Research reveals in its new report that the market drivers of this ... growing need for better diagnostics as part of a molecular diagnostics trend. , The ...
(Date:7/1/2015)... 1, 2015   Neuraltus Pharmaceuticals, Inc. , a ... groundbreaking drugs to treat neurodegenerative diseases such as ... Robert G. Miller , M.D., Director of the Forbes ... Pacific Medical Center in San Francisco, has been awarded ... million to help fund a Phase 2 clinical ...
Breaking Biology Technology:In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3AgBiome and Genective collaborate to create novel insect-resistant crops 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4
... Company Initial $250,000 under March ... ... (OTC,Bulletin Board: BMRX), a leading developer and supplier of consumer-based,finger-activated products, ... and former personnel of Sequiam,Corporation (OTC Bulletin Board: SQUME) through a ...
... 22 Rib-X Pharmaceuticals, Inc.,("Rib-X" or the ... and development of novel antibiotics for the ... Johnson,Ph.D., Chief Research Officer and Vice President, ... Institute,s 2nd Annual "The,Challenge of Antibacterial Development" ...
... April 22 Insmed Inc. (Nasdaq:,INSM), a developer ... Geoffrey Allan, Ph.D., CEO of Insmed, will present ... FOBs, on April 29,2008 at 2:15 PM Eastern ... "Evaluate the Legislative, Economic and,Scientific Implications of the ...
Cached Biology Technology:bioMETRX, Inc. Initiates Integration of Personnel and Assets of Sequiam Corp. 2Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institute's 2nd Annual Challenge of Antibacterial Development Conference 2Insmed to Present at CBI Follow-On Biologics Conference 2Insmed to Present at CBI Follow-On Biologics Conference 3
(Date:6/24/2015)... -- The biologics safety testing market is growing at ... include growth of the pharmaceutical and biological industries and ... years, the number of drug approvals in North American ... approved 225 drug applications and Health Canada approved 99. ... accounted for 3,822 of the pharmaceutical and 1,998 ...
(Date:6/23/2015)... 23, 2015   MedNet Solutions , an ... entire spectrum of clinical research, is pleased to ... , the company,s intuitive, flexible and affordable cloud-based ... 2015 Stevie® Award by the American Business ... Website category.  The American Business Awards are considered ...
(Date:6/18/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") ... market announces that its Wocket® smart wallet will be the ... scheduled to air on WABC Radio (am770) in ... The broadcast air- time for the extensive one ... Inc.,s CEO Gino Pereira will be discussing its ...
Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3
... atrial fibrillation (AF) among more than 4,000 participants in the ... relatives was associated with AF risk after adjustment for established ... study that will appear in the November 24 issue of ... because it will be presented at the American Heart Association,s ...
... Wood was presented with the Lifetime Achievement Award for ... Philip Campbell, editor-in-chief of Nature , at the ... earlier this week. Chris Wood, Fellow ... in the Department of Biology at McMaster University (Hamilton, ...
... remarkably versatile divers. Routinely diving to depths of several ... deep as 1250m. The animals probably plumb the depths ... in the tropics. However it wasn,t clear how these ... Sabrina Fossette from Swansea University explains that no one ...
Cached Biology News:Having first-degree relative with atrial fibrillation linked with increased risk 2Nature honors outstanding faculty mentor 2How diving leatherback turtles regulate buoyancy 2
Mouse monoclonal [6C3] to JAB1 ( Abpromise for all tested applications). entrezGeneID: 10987 SwissProtID: O15386...
Recombinant Ovine (Sheep) Prolactin, Ultra Pure...
Human LT beta R/TNFRSF3 Phycoerythrin MAb (Clone 71319)...
Human Serpin A3 MAb (Clone 213907)...
Biology Products: